IMMUNOHISTOCHEMISTRY, 8 MARKER PANEL

Test Name

IMMUNOHISTOCHEMISTRY, 8 MARKER PANEL

Aliases

IHC 8 MARKERS

Abbreviations

IHC X8

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

HISTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

14

TAT Units

DAYS

Test Requirements

Formalin Fixed, Paraffin -Embedded Blocks. Residual tissue must be available on the block. Routinely, staining & reporting service is offered; however, stain & return service (IHC staining only without interpretation) is available for pathologists for interpretation & reporting at their end. Test may not be performed if no indication is found as determined by the reviewing pathologist. Ancillary tests may be indicated at additional cost as determined by the reviewing pathologist. NB: Cost depends on the number of IHC markers (resident pathologist available to give advice).

Clinical Utility

Variable E.g. Diagnosis/ Confirmatory/ Subtyping (E.g. Lymphoid Markers For Confirmation & Subtyping Of Lymphomas; Cytokeratin For Carcinomas; Myogenin Or Desmin For Sarcomas; S100 For Melanomas Etc.); Theranostic Or Prediction Of Response To Targeted Therapy (E.g. ER, PR Results Can Predict Response To Hormonal Therapy; HER2 Results For Response To Herceptin); Prognostic.

Last Review

26th Feb 2026

IMMUNOHISTOCHEMISTRY, 7 MARKER PANEL

Test Name

IMMUNOHISTOCHEMISTRY, 7 MARKER PANEL

Aliases

IHC 7 MARKERS

Abbreviations

IHC X7

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

HISTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

14

TAT Units

DAYS

Test Requirements

Formalin Fixed, Paraffin -Embedded Blocks. Residual tissue must be available on the block. Routinely, staining & reporting service is offered; however, stain & return service (IHC staining only without interpretation) is available for pathologists for interpretation & reporting at their end. Test may not be performed if no indication is found as determined by the reviewing pathologist. Ancillary tests may be indicated at additional cost as determined by the reviewing pathologist. NB: Cost depends on the number of IHC markers (resident pathologist available to give advice).

Clinical Utility

Variable E.g. Diagnosis/ Confirmatory/ Subtyping (E.g. Lymphoid Markers For Confirmation & Subtyping Of Lymphomas; Cytokeratin For Carcinomas; Myogenin Or Desmin For Sarcomas; S100 For Melanomas Etc.); Theranostic Or Prediction Of Response To Targeted Therapy (E.g. ER, PR Results Can Predict Response To Hormonal Therapy; HER2 Results For Response To Herceptin); Prognostic.

Last Review

26th Feb 2026

BREAST CANCER DIAGNOSTIC PANEL I (HISTO + ER, PR, HER2 IHC)

Test Name

BREAST CANCER DIAGNOSTIC PANEL I (HISTO + ER, PR, HER2 IHC)

Aliases

BREAST HISTOPATHOLOGY WITH HORMONE RECEPTOR PANEL; BREAST HISTOPATHOLOGY AND TRIPLE MARKER IHC PANEL, BREAST HISTOPATHOLOGY WITH PROGNOSTIC/PREDICTIVE IHC PANEL

Abbreviations

BREAST PATH WITH ER/PR/HER2

Test Classification

GROUPED TEST

Department

ANATOMIC PATHOLOGY

Sub Department

HISTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

14

TAT Units

DAYS

Test Requirements

Provide clinical history, imaging findings, and prior therapy. Acceptable specimens: 1. Fresh breast tissue in 10% neutral buffered formalin (NBF); place in fixative immediately after excision OR 2. FFPE blocks OR 3. Unstained slides (3–5 µm). For IHC positively charged slides. Fixation requirements: 6–72 hours in 10% NBF; avoid over-fixation or under-fixation. Tissue quality: Representative tumor tissue with minimal crush or thermal artifact. Test components: Histology with ER, PR, and HER 2 IHC.

Clinical Utility

Confirms malignancy and subtype. Determines hormone-receptor status to guide endocrine therapy. Determines HER2 status for anti-HER2 therapy eligibility. Forms the basis of molecular surrogate classification (e.g., Luminal vs HER2-enriched vs Basal-like).

Last Review

26th Feb 2026

SECOND OPINION (SLIDES AND BLOCKS)

Test Name

SECOND OPINION (SLIDES AND BLOCKS)

Aliases

HISTOLOGY SECOND OPINION, HISTOPATHOLOGY CONSULT BLOCK, SURGICAL PATHOLOGY CONSULTATION

Abbreviations

-

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

HISTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

14

TAT Units

DAYS

Test Requirements

Formalin fixed paraffin embedded block(s) +/- H&E stained slides. Original histology (H&E) report plus detailed clinical information inclusive of imaging findings where applicable is MANDATORY. Does NOT include IHC. If required, additional charges for IHC apply.

Clinical Utility

A second-opinion review of histology or cytology helps confirm the original diagnosis of an externally reported case, especially in difficult, rare, or high-risk cases. It may also identify errors, clarify uncertain findings, or refine tumor type and grade, which may change treatment decisions. This review increases diagnostic accuracy, builds clinician and patient confidence, and supports appropriate therapy planning, avoiding unnecessary or incorrect treatment.

Last Review

26th Feb 2026

MISMATCH REPAIR (MMR) PROTEIN IMMUNOHISTOCHEMISTRY

Test Name

MISMATCH REPAIR (MMR) PROTEIN IMMUNOHISTOCHEMISTRY

Aliases

MMR IHC

Abbreviations

-

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

HISTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

14

TAT Units

DAYS

Test Requirements

Formalin fixed, paraffin embedded blocks. Residual tissue with tumor must be available on the block. Transport at room temperature (20-25 degrees C); protect from excessive heat. Clinical history and original H&E report are required.

Clinical Utility

Evaluation/ Screening Of Lynch Syndrome Or Hereditary Non-polyposis Colorectal Cancer (HNPCC). Positive results require follow up microsatellite instability (MSI testing For quantification in order to distinguish between high & low MSI. High MSI is associated with poorer prognosis.

Last Review

26th Feb 2026

IMMUNOHISTOCHEMISTRY, 3 MARKER PANEL

Test Name

IMMUNOHISTOCHEMISTRY, 3 MARKER PANEL

Aliases

IHC 3 MARKERS

Abbreviations

IHC X3

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

HISTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

14

TAT Units

DAYS

Test Requirements

Formalin Fixed, Paraffin -Embedded Blocks. Residual tissue must be available on the block. Routinely, staining & reporting service is offered; however, stain & return service (IHC staining only without interpretation) is available for pathologists for interpretation & reporting at their end. Test may not be performed if no indication is found as determined by the reviewing pathologist. Ancillary tests may be indicated at additional cost as determined by the reviewing pathologist. NB: Cost depends on the number of IHC markers (resident pathologist available to give advice).

Clinical Utility

Variable E.g. Diagnosis/ Confirmatory/ Subtyping (E.g. Lymphoid Markers For Confirmation & Subtyping Of Lymphomas; Cytokeratin For Carcinomas; Myogenin Or Desmin For Sarcomas; S100 For Melanomas Etc.); Theranostic Or Prediction Of Response To Targeted Therapy (E.g. ER, PR Results Can Predict Response To Hormonal Therapy; HER2 Results For Response To Herceptin); Prognostic.

Last Review

26th Feb 2026

PAP SMEAR CYTOLOGY REPORTING AND PROCEDURE

Test Name

PAP SMEAR CYTOLOGY REPORTING AND PROCEDURE

Aliases

PAP TEST; PAPANICOLAOU TEST

Abbreviations

-

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

CYTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

7

TAT Units

DAYS

Test Requirements

TEST ORDERING INSTRUCTIONS: Fill out test request form fully & legibly. Provide complete history including last menstrual period (LMP)/ if postmenopausal; contraceptive issue; specific indication (e.g. routine screening vs. follow up of previous abnormal results); appearance of the cervix at the time of sampling. SAMPLE TYPE: Smear of the cervix (on intact, labeled slides). Avoid collection during menses. CONTAINER/ PRESERVATIVE Immediately fixed smears which are labeled with patient details; glass slides should be intact (not broken). Avoid air drying.

Clinical Utility

Screening & diagnosis of cancer of the cervix & its precursors.

Last Review

26th Feb 2026

PAP SMEAR CYTOLOGY REPORTING ONLY

Test Name

PAP SMEAR CYTOLOGY REPORTING ONLY

Aliases

PAP TEST; PAPANICOLAOU TEST

Abbreviations

-

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

CYTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

7

TAT Units

DAYS

Test Requirements

TEST ORDERING INSTRUCTIONS: Fill out test request form fully & legibly. Provide complete history including last menstrual period (LMP)/ if postmenopausal; contraceptive issue; specific indication (e.g. routine screening vs. follow up of previous abnormal results); appearance of the cervix at the time of sampling. SAMPLE TYPE: Smear of the cervix (on intact, labeled slides). Avoid collection during menses. CONTAINER/ PRESERVATIVE Immediately fixed smears which are labeled with patient details; glass slides should be intact (not broken). Avoid air drying.

Clinical Utility

Screening & diagnosis of cancer of the cervix & its precursors.

Last Review

26th Feb 2026

BODY FLUID CYTOLOGY

Test Name

BODY FLUID CYTOLOGY

Aliases

PLEURAL FLUID CYTOLOGY; PERITONEAL/ ASCITIC FLUID CYTOLOGY; SYNOVIAL/ JOINT FLUID CYTOLOGY; PERICARDIAL FLUID CYTOLOGY; CEREBROSPINAL FLUID CYTOLOGY.

Abbreviations

-

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

CYTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

7

TAT Units

DAYS

Test Requirements

TEST ORDERING INSTRUCTIONS: Fill out test request form fully & legibly. Provide your contact information & complete history with relevant investigation details (lab, imaging). Specify the exact fluid source (e.g. pleural fluid, ascitic fluid, CSF, urine, right knee joint fluid etc.). SAMPLE TYPES: Fluid from variable sources. Exact anatomic site and where applicable laterality (left or right) must be specified. CONTAINER/ PRESERVATIVE Provide ≥10mL fluid in sterile, labeled, leak-proof container.

Clinical Utility

Body fluid cytology is a test where fluids from different parts of the body are examined under a microscope. It's helpful for: 1. Detecting cancer cells that have spread to body fluids. 2. Diagnosing infections in fluids like urine or joint fluid. 3. Identifying inflammation in the lungs or abdomen. 4. Checking for abnormal cells in spinal fluid. 5. Monitoring treatment progress for certain conditions. 6. Guiding further medical tests or treatments.

Last Review

26th Feb 2026

FINE NEEDLE ASPIRATION (FNA) CYTOLOGY REPORTING AND PROCEDURE

Test Name

FINE NEEDLE ASPIRATION (FNA) CYTOLOGY REPORTING AND PROCEDURE

Aliases

-

Abbreviations

FNA, FNAC

Test Classification

INDIVIDUAL

Department

ANATOMIC PATHOLOGY

Sub Department

CYTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

7

TAT Units

DAYS

Test Requirements

TEST ORDERING INSTRUCTIONS: Fill out test request form fully & legibly. Provide clinical history. Specify the exact sample type, anatomic site, laterality (where applicable e.g. left vs right) from where the FNA should be obtained. SAMPLE TYPES: Variable e.g. thyroid, breast, lymph node etc. Exact anatomic site must be specified by the person doing collection. COMPONENTS: FNA collection / procedure (requires patient to be physically present) AND reporting (laboratory assessment). CONTAINER/ PRESERVATIVE Fixed smears which are labeled with patient details; glass slides should be intact (not broken). 2 slides should be air dried then methanol fixed; another 2 should be placed directly in ethanol fixative without air drying.

Clinical Utility

Fine needle aspiration cytology (FNAC) is a simple, quick test where a thin needle is used to take a small sample of cells from a lump or growth in the body. It may be performed with or without image guidance. It helps: 1. Check if a lump is cancerous or not. 2. Diagnose thyroid, breast, and lymph node problems. 3. Diagnose infections. 4. Avoid unnecessary surgeries. 5. Guide further testing or treatment. 6. Assess hard-to-reach areas inside the body. It's a useful first step in figuring out what's causing unusual growths or swellings.

Last Review

26th Feb 2026